Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received tobacco cessation intervention if identified as a tobacco user
Three rates are reported:
a. Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months
b. Percentage of patients aged 18 years and older who were identified as a tobacco user who received tobacco cessation intervention
c. Percentage of patients aged 18 years and older who were screened for tobacco use one or more times within 24 months AND who received tobacco cessation intervention if identified as a tobacco user
- Measure TypeElectronic Clinical Quality Measure (eCQM)Level Of AnalysisCare SettingMAT output not attachedAttachedNumerator
Population 1:
Patients who were screened for tobacco use at least once within 24 months
Population 2:
Patients who received tobacco cessation intervention
Population 3:
Patients who were screened for tobacco use at least once within 24 months AND who received tobacco cessation intervention if identified as a tobacco userDenominatorPopulation 1:
All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period
Population 2:
All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement period who were screened for tobacco use and identified as a tobacco user
Population 3:
All patients aged 18 years and older seen for at least two visits or at least one preventive visit during the measurement periodExclusionsDenominator Exclusions: not applicable
Denominator Exceptions:
Population 1:
Documentation of medical reason(s) for not screening for tobacco use (eg, limited life expectancy, other medical reason)
Population 2:
Documentation of medical reason(s) for not providing tobacco cessation intervention (eg, limited life expectancy, other medical reason)
Population 3:
Documentation of medical reason(s) for not screening for tobacco use OR for not providing tobacco cessation intervention for patients identified as tobacco users (eg, limited life expectancy, other medical reason)All information required to stratify the measure resultsOffAll information required to stratify the measure resultsOffTesting Data Sources
- Measure StructureNon Condition SpecificTarget PopulationMeasure Selection AttributesNational Quality Strategy PrioritiesPrevention and Treatment
- Risk AdjustmentRisk adjustment approachOffRisk adjustment approachOffConceptual model for risk adjustmentOffConceptual model for risk adjustmentOff
- Current or planned use(s)Planned Use
- Most Recent Endorsement ActivityPrevention and Population Health Fall 2022Initial EndorsementNext Planned Maintenance ReviewFall 2027Endorsement StatusLast Updated
- Do you have a secondary measure developer point of contact?OffThe measure developer is NOT the same as measure stewardOffSteward Organization EmailSteward Organization Copyright
Copyright 2015 PCPI® Foundation and American Medical Association. All Rights Reserved.
The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.
The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, eg, use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.
Commercial uses of the Measures require a license agreement between the user and the PCPI® Foundation (PCPI®) or the American Medical Association (AMA). Neither the American Medical Association (AMA), nor the AMA-convened Physician Consortium for Performance Improvement® (AMA-PCPI), now known as the PCPI, nor their members shall be responsible for any use of the Measures.
AMA and PCPI encourage use of the Measures by other health care professionals, where appropriate.
THE MEASURES AND SPECIFICATIONS ARE PROVIDED "AS IS" WITHOUT WARRANTY OF ANY KIND.
Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets. The AMA, the PCPI and its members and former members of the AMA-PCPI disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.
CPT® contained in the Measure specifications is copyright 2004-2015 American Medical Association. LOINC® is copyright 2004-2015 Regenstrief Institute, Inc. This material contains SNOMED CLINICAL TERMS (SNOMED CT®) copyright 2004-2015 International Health Terminology Standards Development Organisation (IHTSDO). ICD-10 is copyright 2015 World Health Organization. All Rights Reserved.
- Detailed Measure SpecificationsNoLogic ModelOffImpact and GapNoFeasibility assessment methodology and resultsNoAddress health equityNoMeasure’s use or intended useNo508 ComplianceOffIf no, attest that all information will be provided in other fields in the submission.Off
Effective March 27, 2023, the National Quality Forum (NQF) is no longer the consensus-based entity (CBE) funded through the Centers for Medicare & Medicaid Services (CMS) National Consensus Development and Strategic Planning for Health Care Quality Measurement Contract. Battelle has been selected to oversee the endorsement & maintenance (E&M) of clinical quality and cost/resource use measures. Since the Fall 2022 cycle launched at NQF, measures submitted to this E&M cycle continued along the prior E&M protocols that were in place at time of the Fall 2022 “Intent to Submit.” Battelle took over the E&M work for the Fall 2022 cycle after developers and/or stewards submitted their full measure information to NQF, which for CBE #0028, the most recent measure specifications can be found here: https://p4qm.org/media/2376
Battelle took over the E&M work beginning with the public comment period to close the E&M committees for the post-comment meeting, convening the CSAC to render a final endorsement decision, and executing the appeals period.